Venture Funding Deals, September 2015
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.
You may also be interested in...
Device Debut: Procept Biorobotics Expects To Make A Splash With AquaBeam
The clinical trial data that earned the AquaBeam Aquablation system de novo clearance from US FDA in December shows Aquablation is as effective as transurethral resection of the prostate at treating symptoms of benign prostate hyperplasia, but carries a lower risk of complications associated.
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
ARCH invests $150m in the Scangos-led Vir Biotechnology; Flagship recruits ex-Novartis executive Epstein; Versant closes a new $400m fund; and $601.1m in 11 other recent VC funding rounds.
Deals In Depth: February 2023
Two $1bn+ alliances were penned in February. Topping the list was a potential $1.16bn deal between AstraZeneca and KYM Biosciences (a joint venture company of Keymed Biosciences and Lepu Biopharma, of which Keymed owns 70%). Under the exclusive global agreement, AstraZeneca will develop, manufacture and commercialize CMG901, a Phase I antibody drug conjugate for the treatment of Claudin 18.2-positive solid tumors including gastric cancers.